View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
October 23, 2020updated 12 Jul 2022 11:34am

Interim results of the SOLIDARITY trial failed to show efficacy of repurposed drugs in mortality of hospitalized Covid-19 patients

The World Health Organization’s Phase II/III SOLIDARITY trial for COVID-19 is currently the world’s largest randomized clinical trial for the treatment of COVID-19, with 11,266 patients enrolled from 405 hospitals located in more than 30 countries.

By GlobalData Healthcare

The World Health Organization’s Phase II/III SOLIDARITY trial for COVID-19 is currently the world’s largest randomized clinical trial for the treatment of COVID-19, with 11,266 patients enrolled from 405 hospitals located in more than 30 countries. The trial is designed to investigate the effectiveness of four different drugs or combinations—remdesivir, a combination of lopinavir and ritonavir, interferon beta, and chloroquine or hydroxychloroquine—compared to standard of care in subjects hospitalized with COVID-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Only six months after initiation, interim results were reported on October 15, 2020, that showed that the drug candidates, given by themselves or in combination, had little to no effect on the 28-day mortality or the in-hospital course. In-hospital course included initiation of ventilation and duration of the hospital stay.

One of the surprising results of this trial is that remdesivir showed little to no effect, as remdesivir is the only drug candidate within this trial currently approved for the treatment of COVID-19 and has shown positive data in previous trials. The drug candidate received FDA emergency use authorization back on May 1 and was taken recently by President Donald Trump when he was being treated at Walter Reed Medical Center for COVID-19. The results from the SOLIDARITY trial were not published in a peer-reviewed journal and unlike the previous remdesivir trial by the NIAID that found positive results for patients, the SOLIDARITY trial did not have a placebo, nor was it double-blinded. It is also not clear how sick patients were when they were hospitalized, and because of the variation of healthcare systems in different countries, the criteria for hospitalizing patients may have differed. The SOLIDARITY trial enrolled patients from March to October and during this time the standard of care changed greatly; early on, patients were put on ventilators much faster, whereas now there are studies that have found ventilation in some cases worsens symptoms.

On the other hand, the SOLIDARITY trial did show that large-scale international trials are possible during a pandemic with the possibility of drawing conclusions at a rapid pace, as soon as six months.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena